- Datum19.06.2025
- Uhrzeit14:30 - 15:00 Uhr
- Veranstalter
XTB
Jens Klatt
Moderator
Protagonist Therapeutics Inc. Aktie
Verkaufen
Kaufen
Protagonist Therapeutics Inc. Chart
Protagonist Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Tradegate | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-2,34 %
Intraday
-4,26 %
1 Woche
18,32 %
1 Monat
39,69 %
Seit Jahresbeginn
65,45 %
1 Jahr
586,01 %
3 Jahre
209,17 %
5 Jahre
Passender Service zu Protagonist Therapeutics Inc.
Webinar zu Protagonist Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)30,673-60,600
- Jahrestief / Hoch ($)33,700-60,600
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Protagonist Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Protagonist Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
